INTRODUCTION {#s1}
============

Acute promyelocytic leukemia (APL) is a distinct subset of acute myeloid leukemia (AML), associated with the chromosomal translocation t(15;17)(q22;q12), resulting in *PML-RARA* gene fusion and chimeric protein, which interferes with the maturation process of myeloid cells ([@BOCHTLERMCS001123C20]). Clinical trials report long-term disease-free survival in ∼85% of patients treated with all-*trans* retinoic acid (ATRA) and anthracycline-based chemotherapy ([@BOCHTLERMCS001123C34]). However, ∼10% of patients will suffer relapse. Recently, the therapeutic spectrum has been widened by the introduction of arsenic trioxide (ATO), which in combination with ATRA produced 2-yr event-free survival rates of 97% in patients with low-to-intermediate-risk APL ([@BOCHTLERMCS001123C33]).

The Sanz score, which is based on peripheral leukocyte and platelet counts at presentation, forms the mainstay for risk stratification in APL ([@BOCHTLERMCS001123C42]). Other factors that have been associated with an adverse outcome include CD56 expression and a promoter polymorphism of the *FAS* (also known as *CD95*) gene ([@BOCHTLERMCS001123C36]; [@BOCHTLERMCS001123C46]).

Internal tandem duplications of the *FLT3* gene (*FLT3-*ITD) and point mutations of the *FLT3* tyrosine kinase II domain (*FLT3-*TKD), typically at Asp 835, are detected in 15%--40% and 10%--20% of APL cases, respectively ([@BOCHTLERMCS001123C37]; [@BOCHTLERMCS001123C2]; [@BOCHTLERMCS001123C3]; [@BOCHTLERMCS001123C10]; [@BOCHTLERMCS001123C18]; [@BOCHTLERMCS001123C27]; [@BOCHTLERMCS001123C12]; [@BOCHTLERMCS001123C7]; [@BOCHTLERMCS001123C43]; [@BOCHTLERMCS001123C50]; [@BOCHTLERMCS001123C44]). In APL, *FLT3-*ITD mutations are associated with leukocytosis at presentation but did not independently correlate with response to treatment or survival ([@BOCHTLERMCS001123C37]; [@BOCHTLERMCS001123C3]; [@BOCHTLERMCS001123C18]; [@BOCHTLERMCS001123C28]; [@BOCHTLERMCS001123C8]; [@BOCHTLERMCS001123C38]; [@BOCHTLERMCS001123C44]). No distinct clinical phenotype or consistent impact on prognosis has been identified for *FLT3-*TKD mutations in APL so far, perhaps because of their relative rarity ([@BOCHTLERMCS001123C45]; [@BOCHTLERMCS001123C7]; [@BOCHTLERMCS001123C43]; [@BOCHTLERMCS001123C28]).

Similar to other types of AML, extramedullary manifestations are rare in APL. However, extramedullary relapses have been reported with increasing frequency during the last 20 years, corresponding to the time when ATRA, which penetrates the central nervous system (CNS) poorly, became the mainstay of APL treatment ([@BOCHTLERMCS001123C9]; [@BOCHTLERMCS001123C6]). Approximately 3%--5% of APL patients will experience extramedullary relapse, most commonly in the CNS, with CNS relapse being either isolated or associated with bone marrow relapse ([@BOCHTLERMCS001123C14]; [@BOCHTLERMCS001123C1]; [@BOCHTLERMCS001123C49]). Although high white blood cell counts at diagnosis and prior CNS hemorrhage are established risk factors for CNS relapse, the significance of increased age, differentiation syndrome, CD56 expression, and FLT3-ITD positivity remains unclear ([@BOCHTLERMCS001123C35]; [@BOCHTLERMCS001123C47]; [@BOCHTLERMCS001123C13]).

RESULTS {#s2}
=======

Clinical Presentation and Treatment Outcome {#s2a}
-------------------------------------------

The 48-yr-old female patient was diagnosed with high-risk APL in January 2012. After treatment according to the high-risk arm of the AIDA (ATRA plus idarubicin) protocol with ATRA and chemotherapy ([@BOCHTLERMCS001123C32]), complete molecular remission was achieved by the end of consolidation chemotherapy. Subsequently, maintenance therapy with ATRA was administered. In August 2013, 13 mo after initiation of maintenance, the patient developed meningeal relapse with pleocytosis of 597/µL in the cerebrospinal fluid (CSF) ([Fig. 1](#BOCHTLERMCS001123F1){ref-type="fig"}), which caused headaches and paresthesia of the arms. Meningeal relapse was confirmed by immunophenotyping (CD33^+^, CD13^+/−^, CD34^+/−^, CD11b^−^, HLA-DR^−^, CD117^−^, CD56^−^; [Fig. 1](#BOCHTLERMCS001123F1){ref-type="fig"}), interphase fluorescence in situ hybridization, PML-RARα (promyelocytic leukemia/retinoic acid receptor-α) reverse transcription--polymerase chain reaction (RT-PCR), and brain magnetic resonance imaging. At the time of meningeal relapse, the bone marrow continued to be in complete hematologic remission, although minimal residual disease (MRD) testing was positive for *PML-RARA* by nested RT-PCR without quantifiable load. The patient was treated with intrathecal applications of cytarabine and methotrexate and received ATO/ATRA according to the APL0406 protocol ([@BOCHTLERMCS001123C33]), with the first cycle given over 2 mo and intervals between consolidation cycles shortened to 1 wk to increase dose density. At Day 26 of ATO/ATRA induction, elemental arsenic levels in peripheral blood and CSF were 114 µg/L and 13 µg/L as measured by inductively coupled plasma mass spectrometry. Following neutrophilic differentiation of meningeal APL blasts by Day 42, CSF cell counts normalized by week 8 and complete molecular remission was achieved by week 11 ([Fig. 2](#BOCHTLERMCS001123F2){ref-type="fig"}). The patient continued on ATO/ATRA until February 2014 and on intrathecal chemotherapy until April 2014. For consolidation, the patient was recommended autologous hematopoietic stem cell transplantation with busulfan-based conditioning but opted for a watch-and-wait strategy instead. As of March 2016, with 2 yr of follow-up after the end of salvage treatment, the patient continues to be in complete molecular remission in bone marrow and CSF alike.

![Clinical manifestations of meningeal APL relapse with Giemsa staining (*upper left* panel) and fluorescence-activated cell sorting analysis of CD33, CD34, HLA-DR, CD13, CD11b, CD117, CD56, and CD3 expression from cerebrospinal fluid blasts at relapse. Cells were gated in the side scatter (SSC)/forward scatter (FSC) analysis as shown in the *upper right* panel.](BochtlerMCS001123_F1){#BOCHTLERMCS001123F1}

![Treatment and course of cerebrospinal fluid (CSF) cell counts during 3 mo following relapse. The normalization of the CSF cell count sets in with delay. Ara-C, cytosine arabinoside; MTX, methotrexate; PCR, polymerase chain reaction; PML, promyelocytic leukemia; RARA, retinoic acid receptor-α; iFISH, interphase fluorescence in situ hybridization; ATO, arsenic trioxide; ATRA, all-*trans* retinoic acid.](BochtlerMCS001123_F2){#BOCHTLERMCS001123F2}

Genomic Analysis {#s2b}
----------------

To identify molecular drivers of meningeal relapse, we performed whole-exome sequencing of CSF-derived leukemic cells within NCT MASTER (Molecularly Aided Stratification for Tumor Eradication Research), a clinical sequencing program for advanced-stage cancer across all histologies, which identified a *FLT3-*TKD mutation (p.D835Y, c.2503G\>T) ([Table 1](#BOCHTLERMCS001123TB1){ref-type="table"}). Ultradeep targeted resequencing revealed the heterozygous presence of this mutation, which had not been found at first diagnosis, in virtually all CSF cells (51%, 1000/1961 reads). Of note, the mutation was undetectable (0/1666 reads) in the corresponding MRD-positive bone marrow sample drawn concurrently at meningeal relapse. Next, ultradeep targeted sequencing was performed to trace back the meningeal relapse clone to bone marrow samples obtained during the course of the disease. Interestingly, a small subclone comprising 0.4% (6/1553 reads) of bone marrow cells at first diagnosis already harbored the *FLT3-*TKD mutation, whereas it was undetectable in the bone marrow at all other time points---that is, during ATRA maintenance (0/874 reads), at meningeal relapse (0/1666 reads), and after the first cycle of ATO/ATRA (0/1198 reads) ([Fig. 3](#BOCHTLERMCS001123F3){ref-type="fig"}).

![*FLT3-*TKD subclone architecture based on ultradeep sequencing results, inserted into the time line of the disease course. A heterozygous *FLT3-*TKD mutation was present in virtually all cerebrospinal fluid (CSF) cells at meningeal relapse. Interestingly, the mutation could be traced back to a tiny *FLT3*-TKD clone present in the bone marrow sample from first diagnosis. BM, bone marrow; AIDA, ATRA plus idarubicin; ATRA, all-*trans* retinoic acid; ATO, arsenic trioxide.](BochtlerMCS001123_F3){#BOCHTLERMCS001123F3}

###### 

Somatic mutations in CSF-derived leukemic cells identified by whole-exome sequencing

  Chromosome     Position         Gene         RefSeq accession   Exon     Nucleotide change       VAF       Protein change
  -------------- ---------------- ------------ ------------------ -------- ----------------------- --------- ------------------
  SNVs                                                                                                       
   1q22          155,931,985      *ARHGEF2*    NM_001162383       10       c.G1130T                0.6       p.R377L
   3q25.32       158,449,993      *RARRES1*    NM_002888          1        c.A212G                 0.33      p.N71S
   5q31.3        140,215,358      *PCDHA7*     NM_018910          1        c.G1390A                0.35      p.V464M
   9q21.2        79,320,582       *PRUNE2*     NM_015225          8        c.T6608A                0.43      p.L2203X
   9q33.1        118,974,010      *PAPPA*      NM_002581          4        c.G1717A                0.32      p.V573I
   11p15.1       21,135,209       *NELL1*      NM_006157          13       c.C1375T                0.57      p.R459C
   **13q12.2**   **28,592,642**   ***FLT3***   **NM_004119**      **20**   **c.G2503T**            **0.4**   **p.D835Y**
   13q14.3       52,678,680       *NEK5*       NM_199289          9        c.G563T                 0.38      p.W188L
   14q23.2       62,194,324       *HIF1A*      NM_001243084       6        c.T796G                 0.36      p.F266V
   16q24.2       87,678,376       *JPH3*       NM_020655          2        c.G895A                 0.55      p.G299S
   19p13.2       10,091,528       *COL5A3*     NM_015719          34       c.G2513A                0.5       p.R838H
   20p11.23      18,474,662       *RBBP9*      NM_006606          3        c.T188C                 0.49      p.L63P
   Xq24          117,676,802      *DOCK11*     NM_144658          2        c.T217C                 0.43      p.S73P
  Indels                                                                                                     
   8p22          17,067,557       *ZDHHC2*     NM_016353          9        c.848dupT               0.5       p.I283fs
   8q24.21       128,750,873      *MYC*        NM_002467          2        c.411_412insGACCTTCTG   0.34      p.E137delinsEDLL
   14q32.32      103,592,943      *TNFAIP2*    NM_006291          1        c.150_152del            0.12      p.50_51del
   15q26.1       90,378,824       *AP3S2*      NM_001199058       10       c.1107delC              0.49      p.I369fs

CSF, cerebrospinal fluid; SNVs, single-nucleotide variants; Indels, insertion/deletion mutations; VAF, variant allele frequency.

DISCUSSION {#s3}
==========

From a clinical perspective, this case corroborates the effectiveness of ATO as a relapse treatment and, because of its permeability across the blood--brain barrier ([@BOCHTLERMCS001123C4], [@BOCHTLERMCS001123C5]), as a treatment for meningeal disease. ATO has been described to exert dose-dependent dual effects on APL cells, inducing preferentially apoptosis at high concentrations and differentiation at low concentrations ([@BOCHTLERMCS001123C11]). ATO significantly penetrates into the CSF, leading to CSF arsenic concentrations of ∼20% of the respective plasma levels, with considerable variation between individual patients ([@BOCHTLERMCS001123C4], [@BOCHTLERMCS001123C5]; [@BOCHTLERMCS001123C21]). In our patient, the CSF arsenic concentration reached only 11% of the respective plasma concentration at day 26 of induction treatment, explaining the delayed differentiation effect that became detectable only after several weeks and cautioning us not to stop ATO-based protocols prematurely because of a perceived lack of efficacy.

From a molecular perspective, this case highlights the concept of genetic heterogeneity and selection of the "fittest" subclone as a driving mechanism of leukemia progression and relapse. This concept has recently been illustrated by whole-genome sequencing on paired diagnostic and relapse samples from patients with normal karyotype AML, establishing that relapse clones can originate from a minor subclone at initial diagnosis ([@BOCHTLERMCS001123C15]). Our case corroborates and extends this concept of clonal evolution as pathogenetic mechanism in AML.

Similar to normal karyotype AML, both *FLT3-*ITD and *FLT3-*TKD mutations were recurrently found as cooperating mutations in APL ([@BOCHTLERMCS001123C3]; [@BOCHTLERMCS001123C10]; [@BOCHTLERMCS001123C18]; [@BOCHTLERMCS001123C27]; [@BOCHTLERMCS001123C12]; [@BOCHTLERMCS001123C7]; [@BOCHTLERMCS001123C43]; [@BOCHTLERMCS001123C50]; [@BOCHTLERMCS001123C44]). Several *FLT3*-mutant APL cases with extramedullary relapse manifestations have been published ([@BOCHTLERMCS001123C22]; [@BOCHTLERMCS001123C47]; [@BOCHTLERMCS001123C13]; [@BOCHTLERMCS001123C53]; [@BOCHTLERMCS001123C19]; [@BOCHTLERMCS001123C31]). In the majority of these cases, *FLT3* mutational analysis has only been performed in bone marrow or peripheral blood samples and either at initial diagnosis or relapse, respectively. Interestingly, however, in one patient, a *FLT3*-ITD mutation was detected at the time of combined CNS and bone marrow relapse, whereas the bone marrow at initial APL diagnosis was *FLT3*-ITD-negative ([@BOCHTLERMCS001123C47]). Additionally, a case of meningeal involvement in second relapse of APL was reported recently, which harbored a *FLT3-*ITD mutation, whereas the concurrently drawn bone marrow sample was *FLT3*-ITD-negative ([@BOCHTLERMCS001123C19]). Analogous to our case, the *FLT3*-ITD-positive meningeal clone could be traced back to a minor, although not quantified, subclone in the bone marrow at first relapse.

Recently, it was shown that, analogous to normal hematopoietic cells, the level of C-X-C chemokine receptor 4 (CXCR4) expression on AML cells correlates with stromal cell-derived factor-1 (SDF1, encoded by *CXCL12*)-induced chemotaxis and poor prognosis ([@BOCHTLERMCS001123C41]). Importantly, CXCR4 expression was significantly higher in *FLT3*-ITD mutated when compared with *FLT3* wild-type AML, and cells expressing constitutively active *FLT3*-ITD displayed dramatically enhanced migration toward SDF1/CXCL12 ([@BOCHTLERMCS001123C17]). In addition, SDF1/CXCL12 is highly expressed on the vasculature of the blood--brain barrier where it regulates the entry of leukocytes into the CNS ([@BOCHTLERMCS001123C51]). In conclusion, it appears that *FLT3* mutations favor migration and seeding of APL cells to the CSF sanctuary. The mechanisms of clonal selection in this case are closely intertwined with the biology of this privileged CSF site.

APL cases with meningeal involvement are rare, thereby precluding more systematic analyses on the role of specific mutations for extramedullary disease manifestations. Nevertheless, the above cases, together with the data reported here, strongly suggest a role for *FLT3* mutations in establishment and expansion of APL CNS manifestations.

METHODS {#s4}
=======

Isolation of DNA {#s4a}
----------------

Tissue samples were provided in accordance with the regulations of the National Center for Tumor Diseases (NCT) Heidelberg Tissue Bank and the approval of the Ethics Committee of Heidelberg University. DNA from APL cells and DNA from the normal blood sample were isolated using the AllPrep DNA/RNA/Protein Mini Kit (QIAGEN), followed by quality control and quantification using a Qubit 2.0 Fluorometer (Life Technologies), a 2200 TapeStation system (Agilent), and a 2100 Bioanalyzer system (Agilent).

Whole-Exome Sequencing {#s4b}
----------------------

High-throughput sequencing and data analysis were performed as described ([@BOCHTLERMCS001123C26]). In brief, exome capturing was performed using SureSelect Human All Exon V5+UTRs in-solution capture reagents (Agilent). Briefly, 1.5 µg genomic DNA were fragmented to 150--200 bp (paired-end) insert size with a Covaris S2 device, and 250 ng of Illumina adapter-containing libraries were hybridized with exome baits at 65°C for 16 h. Paired-end sequencing (101 bp) was performed with a HiSeq 2500 instrument (Illumina) in rapid mode.

Mapping and Analysis of Whole-Exome Sequencing Data {#s4c}
---------------------------------------------------

Reads were mapped to the 1000 Genomes Phase 2 assembly of the human reference genome (NCBI build 37.1) using BWA (version 0.6.2) with default parameters and maximum insert size set to 1000 bp ([@BOCHTLERMCS001123C29]). BAM files were sorted with SAMtools (version 0.1.19) ([@BOCHTLERMCS001123C30]), and duplicates were marked with Picard tools (version 1.90). Average target coverage was 116.13× for the CSF leukemia and 113.41× for the bone marrow control. In both, \>80% of the targets had a coverage of at least 40× (see [Table 2](#BOCHTLERMCS001123TB2){ref-type="table"}).

###### 

Sequencing coverage for the leukemic CSF cells and the bone marrow control

  Sample        Percentage of reads aligned   Average read coverage   Number of CCDS r15 sites with ≥10-fold coverage   Percentage of CCDS r15 with ≥10-fold coverage   Percentage of CCDS r15 with ≥20-fold coverage   Percentage of *FLT3* sites (2958 bases) with ≥10-fold coverage
  ------------- ----------------------------- ----------------------- ------------------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------------------------
  Bone marrow   99.65%                        113.41                  46,754,560                                        94.78%                                          89.84%                                          98.72%
  CSF blasts    99.64%                        116.13                  46,758,736                                        94.79%                                          89.84%                                          97.73%

The 49 Mbp of consensus coding sequence (CCDS release 15, ftp://ftp.ncbi.nlm.nih.gov/pub/CCDS/archive/15/CCDS.current.txt dated August 3, 2014) is used as the reference for protein-coding sequence coverage. The CCDS release was downloaded and converted into a BED file containing the exon coordinates with a custom Perl script. Only genes with ccds_status "Public" were considered. Using SAMtools version 0.1.19 ([@BOCHTLERMCS001123C30]) view and coverageBed v2.16.2 ([@BOCHTLERMCS001123C39]), the read number per site was determined for nonduplicate reads with a minimal mapping quality of 1.

CSF, cerebrospinal fluid; CCDS, Consensus Coding DNA Sequence.

For the detection of single-nucleotide variants, we applied our in-house analysis pipeline based on SAMtools mpileup and BCFtools with parameter adjustments to allow for calling of somatic variants with heuristic filtering as previously described ([@BOCHTLERMCS001123C23], [@BOCHTLERMCS001123C24]; [@BOCHTLERMCS001123C52]). After annotation with RefSeq (version September 2013) using ANNOVAR ([@BOCHTLERMCS001123C48]), somatic, nonsilent coding variants of high confidence were selected.

Ultradeep Targeted Resequencing {#s4d}
-------------------------------

For the *FLT3*-D835Y-TKD mutation, ultradeep targeted resequencing was performed.

### Library Preparation and Semiconductor Sequencing {#s4d1}

For library preparation, the multiplex PCR-based Ion Torrent AmpliSeq technology (Life Technologies) with the Cancer HotSpot Panel v2 (IonTorrent/Thermo Fisher Scientific) was used. Amplicon library preparation was performed with the Ion AmpliSeq Library Kit v2.0 using ∼10 ng of DNA. Briefly, the DNA was mixed with the primer pool, containing all primers for generating the 207 amplicons and the AmpliSeq HiFi Master Mix and transferred to a PCR cycler (Bio-Rad). After the end of the PCR, primer end sequences were partially digested using FuPa reagent, followed by the ligation of barcoded sequencing adapters (Ion Xpress Barcode Adapters, Life Technologies). The final library was purified using AMPure XP magnetic beads (Beckman Coulter) and quantified using qPCR (Ion Library Quantitation Kit, Thermo Fisher Scientific) on a StepOne qPCR machine (Thermo Fisher Scientific). The individual libraries were diluted to a final concentration of 100 pM and eight to 10 libraries were pooled and processed to library amplification on Ion Spheres using Ion PGM Template OT2 200 Kit. Unenriched libraries were quality-controlled using Ion Sphere quality control measurement on a QuBit instrument. After library enrichment (Ion OneTouch ES), the library was processed for sequencing using the Ion Torrent 200 bp sequencing v2 chemistry and the barcoded libraries were loaded onto a chip. Our way of pooling eight samples on a 318 chip resulted in a mean coverage of 3000-fold per amplicon.

### Variant Calling and Annotation {#s4d2}

Data analysis was performed using the Ion Torrent Suite Software (version 4.4). After base calling, the reads were aligned against the human genome (hg19) using the TMAP algorithm within the Torrent Suite. Variant calling was performed with the variant caller plugin within the Torrent Suite Software and the IonReporter package using a corresponding BED file containing the coordinates of the amplified regions. Only variants with an allele frequency \>5% and minimum coverage \>100 reads were taken into account. Variant annotation was performed using ANNOVAR ([@BOCHTLERMCS001123C48]). Annotations included information about nucleotide and amino acid changes of RefSeq annotated genes, COSMIC and dbSNP entries, and detection of possible splice site mutations. For data interpretation and verification, the aligned reads were visualized using the IGV browser (Broad Institute) ([@BOCHTLERMCS001123C40]).
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======================
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--------------------------

The raw analytical data have been deposited at the European Genome-phenome Archive (<https://www.ebi.ac.uk/ega/datasets>), accession number EGAS00001001848.
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